- Home
- QURE vs DRTS Comparison
QURE vs DRTS Comparison
Compare QURE & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QURE | DRTS |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | Netherlands | Israel |
| Employees | 248 | 125 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.4M | 546.5M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | QURE | DRTS |
|---|---|---|
| Price | $14.77 | $6.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 3 |
| Target Price | ★ $44.92 | $8.67 |
| AVG Volume (30 Days) | ★ 4.6M | 227.4K |
| Earning Date | 03-02-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,107,000.00 | N/A |
| Revenue This Year | $126.12 | N/A |
| Revenue Next Year | $210.54 | $965.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.76 | $2.30 |
| 52 Week High | $71.50 | $8.60 |
Technical Indicators
Market Signals| Indicator | QURE | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 42.74 | 45.05 |
| Support Level | $13.35 | $6.37 |
| Resistance Level | $15.98 | $7.75 |
| Average True Range (ATR) | 1.43 | 0.42 |
| MACD | 0.28 | -0.04 |
| Stochastic Oscillator | 12.52 | 25.00 |
Price Performance
Historical ComparisonAbout QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.